The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BAT2506 as a biosimilar to reference p ...

After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...

Microbes that reside peaceably in the nasal passageways and on the skin can be harnessed for taking drugs to target cells.

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused ...

Drug-resistant infections occur when pathogens change in ways that render antimicrobial drugs ineffective. As a result, the pathogens survive and continue to spread. When infections are treatable with ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Continuous manufacturing (CM) has become a contentious topic in the modern pharmaceutical lexicon, driven by divergent ...

BMS said Camzyos is the first drug to target the underlying disease pathology in obstructive HCM, a progressive disease that thickens the heart walls and makes it harder for the heart to expand ...

Oxide nanoparticles, particularly iron oxide, ceria and silica nanoparticles, hold significant promise for biomedical applications owing to their unique magnetic, catalytic and porous properties ...